SKOKIE, Ill., April 10 /PRNewswire/ -- NanoInk, Inc., an emerging growth technology company specializing in nanometer-scale manufacturing and applications development in the lifescience and semiconductor industries, today announced the appointment of JoAnne Smith Joyce as a member of the Company’s senior management team.
(Logo: http://www.newscom.com/cgi-bin/prnh/20060410/NANOLOGO )
Ms. Joyce has been named Senior Vice President and General Counsel and will report to NanoInk President and Chief Executive Officer Cedric Loiret-Bernal, M.D. Ms. Joyce will head all legal activities, including management of the Company’s intellectual property strategy and transactional work. She will also manage outside counsel, Foley & Lardner and Seyfarth Shaw.
Ms. Joyce brings 19 years of legal experience to NanoInk with a special focus on transactional work, intellectual property and litigation. Most recently, Ms. Joyce worked at Great Lakes Chemical Corp., where she served as Vice President and General Counsel for its Performance Chemicals division. Prior to her position at Great Lakes, Ms. Joyce worked at Baxter International specializing in product liability and commercial litigation.
She began her legal career as a federal judicial clerk to Senior U.S. District Court Judge George Leighton and as a litigation and appellate law associate at Wildman Harrold Allen & Dixon in Chicago. Ms. Joyce received her law degree from the University of Wisconsin, Madison and graduated with distinction from the University of Illinois at Urbana-Champaign.
“Having JoAnne on our management team will be a great advantage for NanoInk since she brings an invaluable expertise in intellectual property strategy and partnership contracts. She has thrived in a wide variety of industries and brings additional Fortune 500 experience to our Company,” said Dr. Loiret-Bernal.
Ms. Joyce will guide NanoInk’s legal strategy as the Company increases revenues by focusing on Nanonencryption(TM) technology that prevents fraudulent pharmaceutical products from entering the global markets. Fraudulent pharmaceutical products are estimated to cost the industry over $25 billion annually.
About NanoInk
NanoInk, Inc. is an emerging growth technology company specializing in nanometer-scale manufacturing and applications development for the lifescience and semiconductor industries. With DPN(R), a patented and proprietary nanofabrication technology that allows for unmatched flexibility, accuracy and also its high-resolution Nanoencryption(TM) technology, NanoInk is able to offer its pharmaceutical customers innovative solutions to fight counterfeiting and illegal diversion of blockbuster pharmaceutical products. Other key applications include nanoscale additive repair, and nanoscale rapid prototyping. Located in the new Illinois Science + Technology Park, north of Chicago, NanoInk currently has over 100 patent and patent applications filed worldwide and has licensing agreements with Northwestern University, Stanford University, and the University of Illinois at Urbana-Champaign. For more information on products and services offered by NanoInk, Inc., see http://www.nanoink.net .
NOTE: NanoInk and the NanoInk logo are registered trademarks owned by NanoInk, Inc.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20060410/NANOLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comNanoInk, Inc.
CONTACT: Dileep R. Gangolli, Investor Relations and FinancialCommunications of NanoInk, Inc., +1-847-745-3635, ir@nanoink.net
Web site: http://www.nanoink.net/
